Bronstein, Gewirtz & Grossman, LLC announced that a securities class action has been filed against Fractyl Health, Inc. and certain officers on behalf of investors who purchased or otherwise acquired Fractyl securities between January 13, 2025, and January 29, 2026. Robbins LLP has also publicized the litigation. The complaints allege that Fractyl misrepresented Revita's effectiveness and prospects and failed to disclose operational problems at one or more REMAIN-1 Midpoint Cohort clinical sites that may have compromised efficacy results. Fractyl reported six-month data on January 29, 2026, showing 4.5% weight regain among Revita-treated patients versus 7.5% in the sham arm, while noting that the cohort was not sufficiently powered for efficacy analysis. The stock fell 68.03% to $0.585 that day and declined another 21.7% to $0.46 on January 30 after Morgan Stanley downgraded the shares and cut its price target. Investors seeking appointment as lead plaintiff must act by October 20, 2026; participation in any recovery does not require serving as lead plaintiff.